Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of dose-dense epirubicin/taxane/CMF regimens in high-risk breast cancer
ACTRN12610000151033Phase 3Completed
- Sponsor
- HeCOG
- Start
- Jul 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, paclitaxel, docetaxel, cyclophosphamide, methotrexate and 2 more in breast cancer (3 arms), sponsored by HeCOG. Primary endpoints: Disease-free survival and Overall survival. Started Jul 2005; status: completed.
02
Drugs
epirubicinpaclitaxeldocetaxelcyclophosphamidemethotrexate
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12610000151033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000151033.